Cardiology Today’s Intervention has compiled a list of the top 5 articles posted to Healio.com/Intervention in May.
This month, our readers were most interested in the results of the SPYRAL HTN-ON MED and RADIANCE-HTN SOLO trials, identifying predictors of poor outcomes with a novel transcatheter aortic valve replacement system, the FDA approval of a new-generation everolimus-eluting stent, the results of the AIDA trial, calculation of noninvasive functional SYNTAX score, and much more.
Hope for renal denervation revived with new sham-controlled trials
Two sham-controlled trials demonstrating the efficacy of renal denervation presented at EuroPCR have rekindled hope for the technology as a treatment for hypertension.
The SPYRAL HTN-ON MED and RADIANCE-HTN SOLO trials tested two different devices in two different patient populations, but results from both studies linked renal denervation with significant reductions in BP on several assessments with little to no safety concerns.
Predictors of poor outcomes with novel TAVR system identified
Calcification and other factors were predictors of paravalvular leakage and permanent pacemaker implantation in patients treated with a TAVR system, researchers reported at EuroPCR.
Won-Keun Kim, MD, from the department of cardiology at Kerckhoff Heart Center in Bad Nauheim, Germany, and colleagues analyzed 500 patients (median age, 82 years; 65% women) who underwent TAVR with a self-expanding nitinol system (Acurate Neo, Symetis/Boston Scientific). The device is not yet approved for use in the United States.
New iteration of EES receives FDA approval
Abbott announced that a new generation of an everolimus-eluting coronary stent system for treatment of patients with complex blockages associated with CAD has received approval from the FDA.
Compared with prior generations, the coronary stent system (Xience Sierra, Abbott) has a thinner profile, longer lengths, increased flexibility and small diameters to access multiple or totally blocked vessels in patients, according to a press release from the company.
AIDA: BVS noninferior to EES in TVF, but confers higher device thrombosis
A bioresorbable vascular scaffold was noninferior to an EES for target vessel failure but conferred higher rates of device thrombosis and target vessel MI, according to the complete 2-year results of the all-comers AIDA trial presented at EuroPCR.
The findings were consistent with preliminary 2-year results published in March 2017 and previously reported by Cardiology Today’s Intervention.
Calculation of noninvasive functional SYNTAX score feasible, accurate
The functional SYNTAX score can be calculated noninvasively and is comparable to calculations using invasive pressure-wire assessment, according to results of a SYNTAX II substudy.
The findings were presented at EuroPCR and simultaneously published in the Journal of the American College of Cardiology.